|Bid||1.6300 x 900|
|Ask||1.6800 x 2900|
|Day's Range||1.5800 - 1.6600|
|52 Week Range||1.1600 - 6.6100|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 28, 2022 - Apr 01, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.88|
Even if it's not a huge purchase, we think it was good to see that Braden Leonard, a Gemini Therapeutics, Inc...
Remote-First-Company/Mass., March 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021.
Remote-First-Company/Mass., February 28, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring.